Tinzaparin blood-thinner and biomarkers after ovarian cancer surgery
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether the blood thinner tinzaparin used after neoadjuvant treatment can change blood markers (“biomarkers”) in people with certain stages of ovarian cancer. It aims to understand if tinzaparin affects the body’s cancer-related signals, which could help future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree in writing to take part in the study
- You are 18 years or older
- Your cancer is epithelial ovarian, fallopian tube, or peritoneal cancer (or an abdominal cancer that biopsy shows started in those areas), and it is high-grade serous, endometrioid, or clear cell
- Your cancer is FIGO stage III or IV and you are planning platinum-based chemotherapy
- Your blood counts and kidney function must be high enough: eGFR 30 or higher, and platelets at least 100
- You cannot currently be pregnant or breastfeeding, and you must use reliable birth control if you could get pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This early-phase study tests SZ011 in people with ovarian epithelial cancer that has come back or did not respond to standard first treatment. You may qualify if your tumor shows a specific marker (mesothelin) and your health tests are strong enough to safely receive the study drug.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.